Astrazeneca's (AZN) cancer treatment imfinzi received an expanded recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to include muscle invasive bladder cancer as a new indication.

Imfinzi together with gemcitabine and cisplatin as a neoadjuvant treatment is indicated to treat adults with resectable muscle invasive bladder cancer, the agency said.